Qianliening Capsule Promotes Mitochondrial Pathway Mediated the Apoptosis of Benign Prostatic Hyperplasia Epithelial-1 Cells by Regulating the miRNA-181a

International Journal of Gerontology - Tập 12 - Trang 244-250 - 2018
Jianheng Zhou1, Xiaoyong Zhong2, Jiumao Lin3, Zhenfeng Hong3
1College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350122, PR China
2Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350004, PR China
3Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, PR China

Tài liệu tham khảo

Harman, 2001, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging, J Clin Endocrinol Metab, 86, 724, 10.1210/jcem.86.2.7219 Untergasser, 2005, Benign prostatic hyperplasia: age-related tissue-remodeling, Exp Gerontol, 40, 121, 10.1016/j.exger.2004.12.008 Lucia, 2008, Growth factors in benign prostatic hyperplasia. Basic science implications, Curr Urol Rep, 9, 272, 10.1007/s11934-008-0048-6 Sciarra, 2008, Prostate growth and inflammation, J Steroid Biochem Mol Biol, 108, 254, 10.1016/j.jsbmb.2007.09.013 Paolone, 2010, Benign prostatic hyperplasia, Clin Geriatr Med, 26, 223, 10.1016/j.cger.2010.02.010 Nicholson, 1999, Caspase Structure, proteolytic substrates, and function during apoptotic cell death, Cell Death Differ, 6, 1028, 10.1038/sj.cdd.4400598 Wang, 2005, Pathways to caspase activation, Cell Biol Int, 29, 489, 10.1016/j.cellbi.2005.04.001 Burlacu, 2003, Regulation of apoptosis by Bcl-2 family proteins, J Cell Mol Med, 7, 249, 10.1111/j.1582-4934.2003.tb00225.x Milosevic, 2003, The DNA damage- induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases, Oncogene, 22, 6852, 10.1038/sj.onc.1206716 Cimmino, 2005, miR-15 and miR-16 induce apoptosis by targeting BCL-2, Proc Natl Acad Sci USA, 102, 13944, 10.1073/pnas.0506654102 Si, 2007, miR-21-mediated tumor growth, Oncogene, 26, 2799, 10.1038/sj.onc.1210083 Gillies, 2007, Regulation of p27Kip1 by miRNA 221/222 in glioblastoma, Cell Cycle, 6, 2005, 10.4161/cc.6.16.4526 Cimmino, 2005, miR- 15 and miR- 16 induce apoptosis by targeting BCL2, Proc Natl Acad Sci USA, 102, 13944, 10.1073/pnas.0506654102 Galluzzi, 2010, miR-181a and miR- 630 regulate cisplatin- induced cancer cell death, Cancer Res, 70, 1793, 10.1158/0008-5472.CAN-09-3112 Lin, 2013, Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway, Exp Ther Med, 5, 1293, 10.3892/etm.2013.1008 Zheng, 2013, Qianliening capsule treats benign prostatic hyperplasia via induction of prostatic cell apoptosis, Mol Med Rep, 7, 848, 10.3892/mmr.2013.1265 Zhou, 2012, Qianliening capsule treats benign prostatic hyperplasia through regulating the expression of sex hormones, estrogen receptor and androgen receptor, Afr J Pharm Pharmacol, 6, 173, 10.5897/AJPP11.547 Lin, 2014, Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1α signaling pathway, Exp Ther Med, 8, 118, 10.3892/etm.2014.1723 Zhou, 2010, Effects of Qianliening capsule on the expression of IL-10 and TNF-α in benign prostatic hyperplasia, Chin Arch Tradit Chin Med, 28, 2569 Zhong, 1999, Overexpression of hypo xia inducible factor 1 alpha in common human cancers and their metastases, Cancer Res, 59, 5830 Lai, 2009, Rhein induced apoptosis through the endoplasmic reticulum stress, caspase and mitochondria-dependent pathways in SCC-4 human tongue squamous cancer cells, In Vivo, 23, 309 Chen, 2007, Caspase-9-induced mitochondrial disruption through cleavage of anti-apoptotic Bcl-2 family members, J Biol Chem, 282, 33888, 10.1074/jbc.M702969200 Cimmino, 2005, miR- 15 and miR- 16 induce apoptosis by targeting BCL2, Proc Natl Acad Sci USA, 102, 13944, 10.1073/pnas.0506654102 Huang, 2010, Biological functions of mocirRNAs, Bioorg Khim, 36, 747 Galluzzi, 2010, miR-181a and miR-630 regulate cisplatin-induced cancer cell death, Cancer Res, 70, 1793, 10.1158/0008-5472.CAN-09-3112